[Successful treatment of a persistent rhino-cerebral mucormycosis in a pediatric patient with a debut of acute lymphoblastic leukemia].

The fungi of the order Mucorales cause mucormycosis, which usually presents as an invasive fungal disease with rapid angioinvasion in immunocompromised patients. Rhinocerebral is the most common presentation. The lipid formulations of amphotericin B are used as primary treatment in invasive mucormycosis; the combined use of posaconazole could allow a reduction in the dose of amphotericin B improving tolerance and adherence to treatment. Caspofungin and amphotericin B association has been shown to be synergistic in vitro and effective in murine models. We present the case of a preschool patient that during the debut of acute lymphoblastic leukemia developed a rhinocerebral mucormycosis successfully responding to antifungal treatment with the combination of liposomal amphotericin and caspofungin.

[1]  J. Guarro,et al.  Mucormycosis in children: a study of 22 cases in a Mexican hospital , 2014, Mycoses.

[2]  A. Kolbin,et al.  Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia , 2014, Mycoses.

[3]  A. Ibrahim,et al.  Isavuconazole Therapy Protects Immunosuppressed Mice from Mucormycosis , 2014, Antimicrobial Agents and Chemotherapy.

[4]  R. Soiffer,et al.  Isavuconazole Treatment of a Patient with Disseminated Mucormycosis , 2014, Journal of Clinical Microbiology.

[5]  D. Falci,et al.  Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections , 2013, Infection and drug resistance.

[6]  T. Zaoutis,et al.  Trends in zygomycosis in children , 2012, Mycoses.

[7]  D. Kontoyiannis,et al.  Epidemiology and clinical manifestations of mucormycosis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  K. Kwon-Chung Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Perfect The impact of the host on fungal infections. , 2012, The American journal of medicine.

[10]  V. D. Singh,et al.  Rhinocerebral mucormycosis—a case report , 2012, Oral and Maxillofacial Surgery.

[11]  A. Attarbaschi,et al.  Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases , 2011, Mycoses.

[12]  J. Carratalà,et al.  [Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update]. , 2011, Enfermedades infecciosas y microbiologia clinica.

[13]  E. Roilides,et al.  Best practice in treating infants and children with proven, probable or suspected invasive fungal infections , 2011, Current opinion in infectious diseases.

[14]  A. Attarbaschi,et al.  Posaconazole salvage treatment in paediatric patients: a multicentre survey , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[15]  J. Perfect,et al.  Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis. , 2009, Clinics in chest medicine.

[16]  Muhammad Ibrahim,et al.  Rhinocerebral mucormycosis in a 12-year-old girl. , 2009, Archives of neurology.

[17]  R. Goldberg,et al.  Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  T. Walsh,et al.  Zygomycosis in Children: A Systematic Review and Analysis of Reported Cases , 2007, The Pediatric infectious disease journal.

[19]  J. Guinea,et al.  Zigomicetos y zigomicosis en la era de las nuevas terapias antifúngicas , 2007 .

[20]  M. Vekemans,et al.  Zygomycosis in the immunocompromised patient: a case report. , 2006, Acta bio-medica : Atenei Parmensis.

[21]  Brad Spellberg,et al.  Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management , 2005, Clinical Microbiology Reviews.

[22]  Russell E. Lewis,et al.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.

[23]  B. Spellberg,et al.  Combination Therapy with Amphotericin B Lipid Complex and Caspofungin Acetate of Disseminated Zygomycosis in Diabetic Ketoacidotic Mice , 2005, Antimicrobial Agents and Chemotherapy.